Vos S J B, Visser P J, Verhey F R J
Afdeling Psychiatrie en Neurophyschologie, MUMC, Maastricht.
Tijdschr Psychiatr. 2011;53(9):647-53.
Biomarkers in cerebrospinal fluid (CSF) are being used increasingly to diagnose early Alzheimer's disease (AD). A CSF profile that is suggestive of ad is an abnormal ratio of the proteins Ab1-42 to total tau.
To describe the prevalence and prognosis of a CSF profile in patients without dementia but with subjective memory problems and mild cognitive impairments (MCI) at a memory clinic.
A multi-centre study.
A European multi-centre study showed that a CSF AD profile was often present in patients with subjective complaints and patients with MCI . The CSF AD profile predicted a decline in cognition and daily functioning over a period of 3 years in patients with MCI. Patients with amnestic MCI and a CSF AD profile developed AD more often within this period than patients without this profile.
CSF markers suggestive of ad are common in persons without dementia. It may be possible to use these markers for the prognosis of patients who have MCI .
脑脊液（CSF）中的生物标志物越来越多地用于早期阿尔茨海默病（AD）的诊断。提示AD的脑脊液特征是蛋白质Ab1-42与总tau蛋白的比例异常。
描述记忆门诊中无痴呆但有主观记忆问题和轻度认知障碍（MCI）患者脑脊液特征的患病率和预后。
一项多中心研究。
一项欧洲多中心研究表明，主观主诉患者和MCI患者中常出现脑脊液AD特征。脑脊液AD特征预测MCI患者在3年内认知和日常功能会下降。在此期间，遗忘型MCI且有脑脊液AD特征的患者比无此特征的患者更常发展为AD。
提示AD的脑脊液标志物在无痴呆的人群中很常见。使用这些标志物预测MCI患者的预后可能是可行的。
